Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 6Breast Neoplasms 5Prostatic Neoplasms 4Hematologic Neoplasms 4Colorectal Neoplasms 4Melanoma 3Lung Neoplasms 3Pancreatic Neoplasms 2Malignant Solid Neoplasm 2Leukemia, Myeloid, Acute 2Hematopoietic and Lymphatic System Neoplasm 2Head and Neck Neoplasms 2COVID-19 2Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spondylitis, Ankylosing 1Speech 1Seroma 1Rectal Neoplasms 1Psoriasis 1Progressive Metastatic Castrate Resistant Prostate Cancer 1Postoperative Complications 1Peritoneal Neoplasms 1Parotid Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Cytarabine 5Whole-Body Irradiation 3Specimen Handling 3Injections 3CPX-351 3Blood Specimen Collection 3venetoclax 2luspatercept 2ivosidenib 2fludarabine phosphate 2fludarabine 2decitabine and cedazuridine drug combination 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Melphalan 2Liposomes 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Gemtuzumab 2Filgrastim 2Daunorubicin 2Cyclosporine 2Cyclophosphamide 2Busulfan 2Biopsy 2Azacitidine 2tocilizumab 1selinexor 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × Standard of Care × 30 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡